Regenxbio gene therapy trials suspended by FDA over safety worries [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
Regenxbio lost almost a fifth of its value Wednesday after the Food and Drug Administration placed a clinical hold on two of the company's experimental gene therapies. Regulators acted after researchers found a case of brain cancer in a 5-year-old child who had received one of the treatments, RGX-111, four years earlier. The agency decided to extend the hold to the second therapy, RGX-121, because of similarities between the two and “shared risk between the clinical studies,” Regenxbio said Wednesday. The company said there has been no causal link between RGX-111 and the child's condition and emphasized that RGX-121 is a separate therapy with years of safety data. "We are surprised by FDA's decision to place our RGX-121 program on hold while the investigation of this single, inconclusive incident in RGX-111 continues," CEO Curran Simpson said in the statement. The news is “confusing and unexpected,” Leerink Partners analyst Mani Foroohar wrote in a note to clients. The hold com
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNXPR Newswire
- Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA ActionPR Newswire
- REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.MarketBeat
- INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLCGlobeNewswire
RGNX
Earnings
- 11/6/25 - Beat
RGNX
Sec Filings
- 1/29/26 - Form 4
- 1/28/26 - Form 8-K
- 1/21/26 - Form SCHEDULE
- RGNX's page on the SEC website